ANGLE plc Revenue and Competitors

UK

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • ANGLE plc's estimated annual revenue is currently $48.2M per year.(i)
  • ANGLE plc's estimated revenue per employee is $251,000

Employee Data

  • ANGLE plc has 192 Employees.(i)
  • ANGLE plc grew their employee count by 9% last year.

ANGLE plc's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Cell Biology, Technology Transfer and OperationsReveal Email/Phone
3
SVP Commercial OperationsReveal Email/Phone
4
Head Medical Writing and Corporate InsightReveal Email/Phone
5
Head OperationsReveal Email/Phone
6
Head Clinical LaboratoriesReveal Email/Phone
7
VP EngineeringReveal Email/Phone
8
Head Medical Writing and Corporate InsightReveal Email/Phone
9
Head MarketingReveal Email/Phone
10
Chief Commercial Officer (CCO)Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$86.6M3452%N/AN/A
#2
$369.5M920-23%$974.7MN/A
#3
$1M40%N/AN/A
#4
$258.8M103118%N/AN/A
#5
$136M5428%N/AN/A
#6
$19.8M79-2%N/AN/A
#7
$51.7M2067%N/AN/A
#8
$40.9M16310%N/AN/A
#9
$85.1M3399%N/AN/A
#10
$40.4M1618%N/AN/A
Add Company

What Is ANGLE plc?

ANGLE plc is a specialized medical diagnostics company with products in the cancer diagnostics and fetal health markets. \r\n\r\nANGLE plc’s lead product, the Parsortix cell separation system, captures very rare cells from blood. \r\n\r\nThis includes circulating tumor cells (CTCs) in cancer patient blood – even when there is less than one CTC\r\nper billion healthy cells. \r\n\r\nThe resulting liquid biopsy allows investigation of mutations in the patient’s cancer, and enables precision medicine. ANGLE plc has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. The FDA approval process is underway for the clinical market in the US.

keywords:N/A

N/A

Total Funding

192

Number of Employees

$48.2M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ANGLE plc News

2022-04-17 - Angle PLC Announces Notice of Preliminary Results and ...

Published: Apr 20, 2022. GUILDFORD, UK / ACCESSWIRE / April 20, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company,...

2022-04-13 - Angle PLC Announces Poster on Parsortix System Presented ...

GUILDFORD, UK / ACCESSWIRE / April 14, 2022 / ANGLE plc ("the Company") (AIM:AGL),(OTCQX:ANPCY), a world-leading liquid biopsy company,...

2022-03-22 - Angle PLC Announces Identifying Therapeutic Targets in ...

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating...

2021-11-02 - Interim Report June 2021

Transforming cancer care with a liquid biopsy based on a simple blood test ANGLE plc Interim Report for the six months ended 30 June 2021 ANGLE plc Interim Results ANGLE plc (AIM:AGL OTCQX:ANPCY), a world leading liquid biopsy company, released on 30 September 2021, its unaudited interim fin ...

2021-09-30 - Presentation slides 30 September 2021: Interim Results for the six months ended 30 June 2021

Interim results for the six months ended 30 June 2021 Andrew Newland and Ian Griffiths 30 September 2021 LSE AIM:AGL OTCQX:ANPCY Legal disclaimer This presentation has been prepared by ANGLE plc (the "Company"). By attending this presentation and/or reviewing the slides you agree to be bou ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$30.6M192N/AN/A
#2
$30.6M192N/AN/A
#3
$37M1925%N/A
#4
$38M1925%N/A
#5
$46.5M1927%N/A